Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — Investor Presentation (May 2019)
32 slides from Elixinol Wellness's investor presentation, May 13, 2019
Slide 1: Elixinol Global to Present at Upcoming U.S. Investor Conferences
Elixinol Global to Present at Upcoming U.S. Investor Conferences For personal use only SYDNEY, May 13, 2019 – Elixinol Global Limited (EXL or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp, dietary supplements and emerging medicinal cannabis sectors, is attend
Slide 2: Investor relations and media contacts
See more at www.elixinolglobal.com For personal use only U.S. Investor Relations Contact: Cody Slach Managing Director, Gateway IR USIR@elixinolglobal.com +1 949 574 3860 Australian Investor Relations Contact: Glen Zurcher Account Director, IR Department IR@elixinolglobal.com +61 420 249 299 Media C
Slide 3: Elixinol Global Limited Investor update, May 2019
For personal use only Elixinol Global Limited Investor update, May 2019 ASX: EXL, OTCQX: ELLXF | www.elixinolglobal.com
Slide 4: Disclaimer
Disclaimer For personal use only This presentation contains summary information about Elixinol Global Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuo
Slide 5: Agenda
For personal use only Agenda Cannabis definition 4 Who we are 5 Key highlights for FY2018 / Q1 FY2019 9 Business overview 11 Financial results FY2018 21 Outlook 25 Appendix 28 www.elixinolglobal.com
Slide 6: Cannabis definition
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results For personal use only 4 EXL | Investor update May 2019
Slide 7: Who we are
For personal use only Who we are www.elixinolglobal.com
Slide 8: Who we are
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Who we are For personal use only Benefiting health and wellness in communities around the world Elixinol Global (herein referred to as EXL) is a global consumer brand with products in multiple can
Slide 9: Why we're different
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Why we’re different For personal use only We believe our products represent the highest quality in the market • Widely recognized global brand with industry leading products, delivered in multiple
Slide 10: Corporate overview
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Corporate overview Keymanagement Board and market statistics* team Key market Key statistics1 market statistics* For personal use only Andrew Duff | Non-Executive Chairman ASX: EXL OTCQX: ELLXF Ex
Slide 11: Key highlights
For personal use only Key highlights www.elixinolglobal.com
Slide 12: Key highlights for FY2018 & Q1 FY2019
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Key highlights for FY2018 & Q1 FY2019 (December 31 year end) For personal use only 1 Revenue FY2018 $37.1m vs FY2017 $16.8m, 121% growth Group Underlying EBITDA FY2018 $0.7m vs FY2017 breakeven Re
Slide 13: Business overview
For personal use only Business overview www.elixinolglobal.com
Slide 14: Diversified portfolio
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Diversified portfolio For personal use only FY2018 revenue by business unit Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medical Cannabis Revenue $32.5m (87%)* Revenue $4.9m (13
Slide 15: Strong growth trajectory across key metrics
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strong grow th trajectory across key metrics For personal use only EXL has maintained a strong growth trajectory Revenue Underlying EBITDA A$ million, 31 December year end A$ million, 31 December
Slide 16: Revenue growth by Consumer Products segment, FY2018
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Revenue grow th by Consumer Products segment, FY2018 For personal use only Growth across all revenue segments with a clear strategy to drive higher margin products Elixinol USA Hemp Foods Australi
Slide 17: Quarterly revenue growth
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Quarterly revenue growth For personal use only A$ million, 31 March 2019, PCP Comments • Modest Q1 FY2019 (January to March) growth reported across both wholesale and bulk sales in the US • Revenu
Slide 18: Elixinol Global key growth initiatives
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Elixinol Global key grow th initiatives For personal use only Continued disciplined approach to drive future revenue growth ✓ Increase distribution through US national retail chains (commenced Apr
Slide 19: Elixinol Global, international footprint
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Elixinol Global, international footprint An established platform that can be leveraged for consumer products For personal use only Global platform for growth • Avenues to market established across
Slide 20: Growth Drivers: Elixinol
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Grow th Drivers: Elixinol Firmly positioned to drive revenue growth and take CBD market share For personal use only • Doubling production capacity in the USA with new 12,000 sq. ft. square foot Co
Slide 21: Growth Drivers: Hemp Foods Australia
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Grow th Drivers: Hemp Foods Australia For personal use only Leveraging industry leading position in Australia to further accelerate growth • Solidify #1 market position in Australia for hemp food
Slide 22: Growth Drivers: Nunyara Pharma (Australia)
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Grow th Drivers: Nunyara Pharma (Australia) For personal use only Leveraging US cannabinoid production and formulation expertise for Medical Cannabis Subject to ODC licenses and planning approvals
Slide 23: FY2018 financial results
For personal use only FY2018 financial results www.elixinolglobal.com
Slide 24: Financial summary
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Financial summary Building scale to support expected future growth For personal use only ($m) FY2018 FY2017 ($m) FY2018 FY2017 Commentary ($m) Revenue FY2018 37.1 FY2017 16.8 Revenue Cost of goods
Slide 25: Cash flow
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Cash flow For personal use only Re-investment to facilitate expected future growth ($m) FY2018 FY2017 Commentary Operating activities (5.7) (1.2) Operating cash flow Investing activities (8.5) (0.
Slide 26: Strong financial position
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strong financial position For personal use only Strong cash position and minimal debt ($m) 31 Dec 2018 31 Dec 2017 Commentary Current assets Strong cash position Cash and cash equivalents 42.9 18.
Slide 27: Outlook
For personal use only Outlook www.elixinolglobal.com
Slide 28: Outlook
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Outlook For personal use only EXL’s global investment into top line growth is on track. There is a significant opportunity to grow sales in the US via large national retailers, with ongoing conver
Slide 29: Strategic outlook: delivering on our corporate strategy
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strategic outlook: delivering on our corporate strategy For personal use only Capturing substantial global growth opportunity in hemp- CBD and medical cannabis FY2021 • Global top 3 leadership FY2
Slide 30: Appendix
For personal use only Appendix www.elixinolglobal.com
Slide 31: Reconciliation to FY2018 underlying EBITDA and NPAT
Cannabis Who w e Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Reconciliation to FY2018 underlying EBITDA and NPAT For personal use only ($m) FY2018 Statutory NPAT (0.9) Tax expense 0.4 Depreciation & amortization 0.8 Interest income/finance costs (0.4) Statu
Slide 32: For more information
For personal use only For more information: Investor relations and media please contact: Australia United States of America Glen Zurcher Cody Slach Account Director, IR Department Managing Director, Gateway Investor Relations IR@elixinolglobal.com | +61 420 249 299 USIR@elixinolglobal.com | +1 949 5